Articlenpj biomedical innovations2026
Surface modified electrospun scaffold supports iPSC-derived limbal stem cell function.
Article in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focuses on the development of an electrospun Poly Lactide-co-Glycolic Acid (PLGA) scaffold for ocular surface regeneration, specifically for the treatment of Limbal Stem Cell Deficiency (LSCD). The scaffold is designed to support the attachment, proliferation, and maintenance of induced pluripotent stem cell-derived limbal stem cells (iPSC-LSCs). To address the hydrophobic nature of PLGA and enhance biocompatibility, the scaffold surface was functionalized with extracellular matrix proteins, specifically Collagen IV and Laminin-521, through atmospheric plasma treatment. Micro-perforations were introduced using laser cutting to improve transparency and membrane permeability. Results indicate that Laminin-521 is essential for iPSC-LSC attachment and survival, with enhanced expression of LSC stemness markers and corneal epithelial differentiation markers observed on the functionalized scaffold. These findings suggest that this scaffold can serve as a viable platform for iPSC-LSC transplantation. Future work will focus on refining scaffold design parameters and conducting in vivo studies to assess therapeutic efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.